COMP <GO>
WST vs MRK // REVENUE GROWTH (YOY)
West Pharmaceutical Services Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: WST 5
— MRK 10
▲ REVENUE GROWTH (YOY) LEADER: WST
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
revenue-growth
6.30%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 74.80% | -38.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 20.70% | -2.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 15.3x | +19.40 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 3.42% | -1.82 | MRK | /fcf-yield <GO> |
| Operating Margin | 19.00% | 34.30% | -15.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 28.10% | -12.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 6.30% | 1.30% | +5.00 | WST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 2.26% | -2.05 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 5.19 | +13.87 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | WST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.3 | 56.9 | +18.47 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | WST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 18.4x | +36.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $361.02B | -$331.70B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | MRK REV | WST GROSS % | MRK GROSS % | WST FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $65.01B | 35.9% | 74.8% | $468.9M | $12.36B |
| FY 2024 | $2.89B | $64.17B | 34.5% | 76.3% | $276.4M | $18.10B |
| FY 2023 | $2.95B | $60.12B | 44.0% | 44.0% | $643.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
MRK // BETA 0.92